Endothelial lipase (EL), a phospholipase A1 (PLA 1 ) lipase, has gained attention as a potential therapeutic target for raising high density lipoprotein (HDL) and protection against atherosclerotic plaque formation (1, 2). EL is a secreted enzyme that subsequently becomes associated with the surface of endothelial cells, where it retains its enzymatic activity (1, 2). Therefore, EL resides in proximity with the plasma compartment where it alters lipoproteins and regulates lipoprotein metabolism. Its primary function is the hydrolysis of HDL phospholipids, which increases HDL turnover and decreases HDL cholesterol (HDL-C) and apoA-I content (3-5), resulting in an overall decrease in plasma levels of HDL particles. In addition to reducing plasma HDL-C, EL elicits other proatherogenic effects including increased free fatty acid and lyso PC, monocyte adhesion to the vessel wall (6), and increased plasma small dense LDL levels (7). EL is expressed in mouse aorta (8) and its expression is upregulated in response to various inflammatory mediators to such as IL-1β, TNFα (9) and INFγ (10). EL expression is also upregulated in the aortas of apo E -/-mice, a model of atherosclerosis (8). Thus, EL's role in lipoprotein metabolism is highly responsive to the proinflammatory conditions found in atherosclerotic plaques.
Endothelial lipase (EL), a phospholipase A1 (PLA 1 ) lipase, has gained attention as a potential therapeutic target for raising high density lipoprotein (HDL) and protection against atherosclerotic plaque formation (1, 2). EL is a secreted enzyme that subsequently becomes associated with the surface of endothelial cells, where it retains its enzymatic activity (1, 2) . Therefore, EL resides in proximity with the plasma compartment where it alters lipoproteins and regulates lipoprotein metabolism. Its primary function is the hydrolysis of HDL phospholipids, which increases HDL turnover and decreases HDL cholesterol (HDL-C) and apoA-I content (3) (4) (5) , resulting in an overall decrease in plasma levels of HDL particles. In addition to reducing plasma HDL-C, EL elicits other proatherogenic effects including increased free fatty acid and lyso PC, monocyte adhesion to the vessel wall (6) , and increased plasma small dense LDL levels
The reason for this discrepancy is not known but may be the result of differences in environmental factors or stage of development of the atherosclerotic lesions at the time of measurement.
Five separate studies have reported human mutations in EL that are associated with increased plasma HDL-C (13, (15) (16) (17) (18) . In particular, two non-synonymous mutations in human subjects were shown to promote elevated HDL by either reduced EL secretion (19) or reduced EL catalytic activity (20) . In addition, EL expression was evident in infiltrating cells, macrophages and smooth muscle cells within human atheromatous plaques (21) . Intriguingly, high levels of plasma EL are correlated with low levels of HDL-C, high levels of small dense LDL, and metabolic syndrome (22) . Elevated EL is also associated with increased visceral adiposity (23) and plasma inflammatory markers (24) . Thus, increases in EL activity may contribute to the low HDL levels observed in patients with obesity and metabolic syndrome. Overall, the data indicate that EL plays an important role in HDL metabolism in humans and that inhibition of EL should increase plasma HDL, especially in patients with low levels of HDL-C. Given the association of low levels of HDL with increased risk of atherosclerotic cardiovascular events in humans 3xFLAG tags at the C-terminus, and then subcloned using unique BamHI and XbaI sites into pVL1393. The final construct was sequence confirmed (Seqwright, Houston, TX).
Spodoptera frugiperda, Sf9, insect cells were routinely maintained between 0.8 X 10 6 and 4.0 X 10 6 cells/ml in ESF921 medium (Expression Systems, Woodland, CA) at 27 o C.
To generate recombinant EL baculovirus, the pVL1393/EL vector was transfected into Sf9 insect cells using BaculoGold transfection kit (BD Biosciences, San Diego, CA)
according to the manufacturer's protocol. Five days post-transfection, passage 0 (P0), virus was harvested and stored at 4°C. High-titer virus (P3) was obtained through two sequential rounds of amplification and used for large-scale production of EL.
Trichoplusia ni, High Five, cells were used for large-scale production. During growth, cells were maintained between 0.3 X 10 6 and 4 X 10 6 cells/mL in ESF921 media at 27°C.
The cells were infected with the recombinant P3 EL baculovirus at a density of ~1.6 X 10 6 cells/mL and an MOI of 1 at 27 o C. Following 72 h of infection, the media was cleared by centrifugation at 800 x g for 10 min at 4°C. Further clarification was achieved with an additional centrifugation at 6000 x g for 10 min at 4°C. Expression was validated by immunoblots using an anti-FLAG (M2) antibody (Sigma).
Media (6 L) was concentrated to 0.7 L on a Kvick Lab system (GE Healthcare, Piscataway, NJ). Concentrated media was buffer exchanged by adding 4 L of 50 mM Tris pH 7.4, 150 mM NaCl (buffer A) and re-concentrated to 0.7 L. Buffer exchanged media was clarified by centrifugation at 6000 x g for 1 h. The cleared media was loaded on a 10 mL anti-FLAG M2 affinity gel (Sigma) at 1 mL/min and 4°C using the AKTA Explorer System (GE Healthcare, Piscataway, NJ 
Assays with HEK293 cells stably expressing lipases
The murine EL (LIPG) cDNA [NM_010720] sequence was modified, optimized for codon preference and fused to an in-frame C-terminal 6xHIS 3xFLAG affinity epitope tag (as described above). The resulting cDNA was subcloned into pcDNA3. 
HUVEC assay
Pooled human umbilical vein endothelial cells, HUVEC (Cambrex/Lonza, Walkersville, MD), were cultured with EBM2 medium containing 5% fetal bovine serum and EGM supplements (Cambrex/Lonza) and plated for assays at a density of 2000 cells/well into BD Collagen coated 384 well plates (BD Biosciences, San Jose, CA) and incubated 24 h at 37°C. Cells were then washed with phosphate buffered saline and incubated with serum-free medium containing 10 ng/ml TNF-α and 1 ng/ml IL-1β for an additional 24 h at 37°C. Medium was removed and replaced with 15 µL assay buffer and assayed as described for the stable HEK293 cell lines.
RESULTS
In order to develop a cell-based assay that would distinguish the activity of a PLA 1 versus a PLA 2 enzyme, we conceived and designed a phospholipid substrate with a BODIPY fluor affixed at the sn-1 position and an alkyl chain attached to the sn-2 position with an ether bond (Fig. 1A) . In addition to the BODIPY fluor, the PLA 1 substrate also contains a dinitrophenyl quencher on the phospholipid head group, allowing for the continuous measurement of fluorescence increase associated with PLA 1 hydrolysis.
Confirmation of activity and appropriate products using purified EL
A depiction of how the PLA 1 substrate is predicted to be hydrolyzed by a PLA 1 enzyme along with its products is presented in Fig. 2A . The prescribed mechanism, an acid/base catalysis with an acyl-enzyme intermediate following the release of product 1 (P1), has been described previously (Fig. 2B) (7, (29) (30) (31) (32) (33) ). SDS PAGE examination of the purified murine EL used in our analysis indicates that our preparation is predominantly intact as shown in Fig. 3C . However, it also contained inactive cleavage products we confirmed by N-terminal sequence analysis, due to partial processing by proprotein convertases, as previously identified by others (34, 35 compared to that of PED6 in a cell-based assay format using cells stably expressing murine EL, human HL or human LPL. As shown in Fig. 5A , under the assay conditions used, the PED6 substrate showed no significant cleavage in cells expressing EL, HL or LPL above non-transfected control cells at all substrate concentrations tested. In contrast to PED6, the PLA 1 substrate demonstrated significant cleavage with these three lipases (Fig. 5B) . The rank order of cleavage was observed to be EL > HL > LPL > untransfected control cells. Moreover, these stably expressing cell lines were determined to have comparable levels of lipase expression (data not shown). EL demonstrated the highest activity on the PLA 1 substrate. This is consistent with its phospholipid preference and strong bias for the sn-1 acyl ester bond (5, 28, 29) .
Inhibition of the PLA 1 substrate cleavage with ebelactone B
We next examined the potential of a small molecule inhibitor, ebelactone B, to block the hydrolytic activity of the PLA 1 lipases in our cell-based assays. Ebelactone B is known to be a promiscuous, covalent inhibitor of lipases (36) . To further explore how the PLA 1 substrate can be used to measure EL activity in a cell-based assay, we used HUVEC cells in which EL expression is known to be upregulated by cytokines (9, 37). Following stimulation with TNF-α and IL-1β, HUVEC cells were used in a cell-based assay with the PLA 1 substrate and increasing concentrations of ebelactone B. As shown in Fig. 7 RFU/min; CV% = 14.9 and the z' factor ranged between 0.46 and 0.70.
DISCUSSION
We conceived and hypothesized the specificity of a novel BODIPY-labeled, selfquenched PLA 1 substrate that could be used in homogeneous high-throughput kinetic assays to measure PLA1-specific phospholipase activities in order to identify small molecular inhibitors of EL as potential therapeutic agents. Since it was not commercially available at the time we contracted the custom synthesis of this substrate at Invitrogen.
EL showed robust phosopholipase activity using this substrate in both cell-free and cellbased assays to monitor its hydrolytic activity. We have routinely run the cell-based PLA 1 substrate assay in a 384-well format. This novel PLA 1 substrate was compared to a widely used PED6 substrate and found to have superior characteristics, making it a more favorable substrate to monitor EL activity. In addition, the PLA 1 substrate can be used to assay the hydrolytic activity of other lipases in counter-screens for monitoring compound selectivity.
Like PED6, the PLA 1 substrate has a BODIPY fluor coupled to a fatty acyl chain and a dinitrophenyl quencher on the phospholipid head group. Unlike PED6, the PLA 1 substrate has the BODIPY fluor coupled to the fatty acyl chain at the sn-1 position.
Further selectivity is designed into the novel PLA 1 substrate by placing a nonhydrolyzable ether bond at the sn-2 position, which prevents hydrolysis at this site by non-specific PLA 2 enzymes.
Other similar fluorescent substrates have been described and used in phospholipid or triglyceride micelles and in synthetic HDL particles in cell-free assays (38) . We saw no particular requirement to incorporate the PLA 1 substrate characterized here into micelles as it could be used directly in either cell-free or in cell-based assays. The critical micelle concentration for the PLA 1 substrate was determined to be approximately 6 µM by fluor titration (unpublished results). Cleavage products were confirmed by LCMS in purified mouse EL as well as a cell-based assay of HEK293 cells expressing human EL (data not shown).
Recently an indirect assay for EL activity has been described using HDL as a substrate by monitoring the liberation of free fatty acids in coupled enzymatic and detection reactions (39) . Even though this assay incorporates HDL, which is the more physiologically relevant substrate for EL, the complex coupled reactions it requires would make analyses of the mode of inhibition difficult and thus inappropriate for guiding chemical optimization of small molecule inhibitors of EL. In addition, although this published assay was used in high throughput fashion, the complex nature of the substrate preparation would make it less convenient and more prone to inter-assay variability compared to the assays presented here.
We attempted to support the physiological relevance of these assays by incorporating the substrate into HDL or HDL-like particles (In collaboration with Roar Biomedical) but were unsuccessful due to dissociation of the substrate from the particles (unpublished observations). We hypothesize that the rapid dissociation was the result of the significantly shorter chain length at the sn-2 position compared to PED6 (Fig. 1) , which has been shown to be useful in an assay incorporated into HDL (40) . To mimic the normal plasma environment for EL activity, we also added plasma to the assay but found the binding of the substrate by BSA resulted in significant release of selfquenching (unpublished observations).
Like LPL and HL, EL is secreted and appears to predominantly remain bound to the cell surface by proteoglycan binding. Although it remains unproven, the cell-surface associated form of EL may constitute the bulk of active EL within the plasma compartment in vivo. Another consideration for this enzyme regarding in vivo activity is the recent finding that EL exists as a head-to-tail dimer. It is possible that this conformation results in a quarternary structure whereby the monomeric units are situated side-by-side (41) . This dimerization occurs intracellularly and is likely present in this form on the cell surface. Since the improved PLA 1 substrate was shown to be amenable to monitoring EL enzymatic activity in cells expressing EL, the assay is able to assess inhibitory activity of compounds against the native form of the enzyme. We used the non-specific esterase inhibitor ebelactone B as an example of how a small molecule inhibitor of lipases can be detected in cell-based assays using the PLA 1 substrate. More recently, a large screening campaign using the described assays resulted in the identification of potent and selective inhibitors of EL which, when administered to animals, resulted in significant increases in HDL-C (manuscript in preparation), which is the expected physiological and therapeutic consequences of in vivo EL inhibition. These recent findings provide important validation for the relevance of the described assays in identifying selective and effective therapeutic inhibitors of EL.
In summary, we have conceived, characterized and validated an improved PLA 1 substrate for use in the screening and characterization of specific inhibitors of EL in both purified enzyme and cell-based activity assay formats. Given that inhibition of EL is a potential therapeutic target for raising HDL-C and inhibiting atherosclerotic disease progression on top of statin therapy (2, 42) , the use of the described assays employing the improved PLA 1 substrate may facilitate the development of selective EL inhibitors for eventual potential evaluation in human disease. 
